Dashboard
Manage Tickers

INVAInnoviva, Inc.

Nasdaq inva.com


$ 16.38 $ 0.20 (1.23 %)    

Friday, 28-Jun-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 16.4
$ 16.18
$ 16.39 x 200
$ 0.00 x 0
$ 16.08 - $ 16.40
$ 12.22 - $ 16.87
729,105
na
1.39B
$ 0.65
$ 7.64
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 07-27-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 04-29-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 07-24-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 10-31-2018 09-30-2018 10-Q
24 07-26-2018 06-30-2018 10-Q
25 05-04-2018 03-31-2018 10-Q
26 02-23-2018 12-31-2017 10-K
27 11-03-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-05-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-24-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-04-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-innoviva
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:38:50

Cantor Fitzgerald analyst Louise Chen reiterates Innoviva (NASDAQ:INVA) with a Overweight.

analyst-projects-strong-growth-for-gsk-innoviva-partnered-respiratory-drugs
Analyst Projects Strong Growth for GSK-Inn...
06/18/2024 17:44:34

Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma...

cantor-fitzgerald-initiates-coverage-on-innoviva-with-overweight-rating
Cantor Fitzgerald Initiates Coverage On In...
06/18/2024 12:10:28

Cantor Fitzgerald analyst Louise Chen initiates coverage on Innoviva (NASDAQ:INVA) with a Overweight rating.

Core News & Articles
Zai Lab And Innoviva Specialty Therapeutic...
05/20/2024 04:40:14

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, ...

innoviva-q1-eps-046-beats-017-estimate-sales-7750m-beat-6800m-estimate
Innoviva Q1 EPS $0.46 Beats $0.17 Estimate...
05/08/2024 21:20:07

Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.17 by 170...

innoviva-specialty-announced-that-positive-results-from-the-phase-3-oral-zoliflodacin-trial-will-be-highlighted-in-an-oral-presentation-at-the-european-society-of-clinical-microbiology-and-infectious-disease-global-congress
Innoviva Specialty Announced That Positive...
04/24/2024 11:12:41

Core News & Articles
Armata Pharmaceuticals Enters Secured Cred...
03/04/2024 21:03:01

The gross proceeds to be received by the Company at closing are $35 million before deducting transaction-related expenses. Proc...

5-value-stocks-in-the-healthcare-sector
5 Value Stocks In The Healthcare Sector
03/04/2024 14:44:45

innoviva-q4-eps-076-beats-023-estimate-sales-8584m-beat-7551m-estimate
Innoviva Q4 EPS $0.76 Beats $0.23 Estimate...
02/29/2024 21:29:29

Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.23 by 230...

innoviva-q3-eps-098-sales-6726m-miss-7565m-estimate
Innoviva Q3 EPS $0.98, Sales $67.26M Miss ...
11/01/2023 21:39:06

Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.27 by 262...

innoviva-q3-eps-098-may-not-compare-to-027-estimate-sales-6726m-miss-7565m-estimate
Innoviva Q3 EPS $0.98 May Not Compare To $...
11/01/2023 21:38:51

Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.27 by 262...

the-global-antibiotic-research--development-partnership-in-collaboration-with-innoviva-specialty-therapeutics-subsidiary-of-innoviva-announced-results-in-largest-pivotal-phase-3-trial-of-a-first-in-class-oral-antibiotic-to-treat-uncomplicated-gonorrhea
The Global Antibiotic Research & Developme...
11/01/2023 21:37:46

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone a...

a-look-into-healthcare-sector-value-stocks
A Look Into Healthcare Sector Value Stocks
10/02/2023 14:43:55

xacduro-the-first-and-only-antibiotic-developed-to-target-acinetobacter-now-available-to-treat-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia-in-adults
XACDURO, The First And Only Antibiotic Dev...
09/18/2023 12:01:21

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumanni...

correction-innoviva-q2-eps-002-misses-026-estimate-sales-8099m-beat-6792m-estimate
CORRECTION: Innoviva Q2 EPS $0.02 Misses $...
08/02/2023 23:21:32

Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.26 by 9...

innoviva-q2-eps-002-misses-026-estimate-sales-8099m-beat-6792m-estimate
Innoviva Q2 EPS $0.02 Misses $0.26 Estimat...
08/02/2023 21:16:47

Innoviva (NASDAQ: INVA) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.26 by ...

overview-of-value-stocks-in-the-healthcare-sector
Overview Of Value Stocks In The Healthcare...
07/31/2023 14:44:59

Core News & Articles
Armata Pharmaceuticals Announces New Finan...
07/11/2023 12:21:45

Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned ...

astrazeneca-spin-off-entasis-secures-fda-approval-for-first-pathogen-targeted-therapy-addressing-acinetobacter
AstraZeneca-Spin Off Entasis Secures FDA A...
05/24/2023 15:49:54

over-125m-bet-on-occidental-petroleum-check-out-these-4-stocks-insiders-are-buying
Over $125M Bet On Occidental Petroleum? Ch...
05/16/2023 13:08:52

Although US stocks closed higher on Monday, there were a few notable insider trades.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)